ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.54 2.2M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 3.60p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.20 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.54.

Evgen Pharma Share Discussion Threads

Showing 12176 to 12197 of 13025 messages
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older
DateSubjectAuthorDiscuss
31/8/2023
12:07
It seems to me that there is still a bigger seller in the background, as MM sold that last 100k after your buy at 2.24p hat.

The lower we go the more likely there are bigger sellers that purchased under 3.5p I guess.

It will be interesting to see at what point there is bounce and a lot of support in the current flat market, and if it bounces at any pace if at all.

clocktower
31/8/2023
11:41
Revalidating my research and taking advantage of the current weakness to top up. So thank you for selling out and any others that have done so.

I don't punt Clock

hatfullofsky
31/8/2023
11:25
Buying back some of what you sold of this in the past by any chance hut, as a punt? :-)

Good Luck either way, I might do the same lower down the food chain.

clocktower
31/8/2023
10:51
BTW I asked GPT to analyse the Phase 1b release, very interesting. Here's an extract :


Changes in Gene Expression: The fact that changes in gene expression were observed indicates that the drug, SFX-01, has effects at a genetic level. This is generally a positive outcome, as it suggests that the drug is interacting with the body's molecular processes in a way that leads to measurable changes.

Effects in Healthy Volunteers: The press release specifically mentions that these gene expression changes were observed "even in healthy volunteers." This is noteworthy because it suggests that the drug's effects on gene expression are not limited to individuals with specific conditions but are observable in a general population. This broader impact could have implications for the drug's potential therapeutic applications.

hatfullofsky
31/8/2023
10:49
Sell volume value is only GBP15k so not a major shareholder. Zero liquidity anywhere in the market and especially at EVG any sells tank the share price

They have cash into Q4 2024 and study results on 3 fronts due this year.

The 100k was a buy, by me

hatfullofsky
31/8/2023
10:45
Have you finished selling clock ?
hatfullofsky
31/8/2023
10:16
You better hope it is not Kight tossing in the towel.
clocktower
31/8/2023
09:18
Someone else seems to be throwing in the towel today. It is going to be a hard task to get back to the target of 7/8p now markth in the next year or two imo.

Good Luck.

clocktower
30/8/2023
22:38
Just thought I would double check hat and took the following from the report:

Share options may be granted under the LTIP as follows:
ï An initial award to Executive Directors on joining the Company to support the recruitment and drive retention.
ï An annual award to Executive Directors and other staff members to be made around the time of the AGM, though this may
be deferred in the event of staff having inside information.
Since 2021 vesting of share options has been subject to; a shareholder return metric (30%), delivery of strategic corporate objectives (40%), and time-vesting 3 years from grant (30%). The aims of this structure are to continue to align senior management remuneration with shareholder returns and to support staff retention.
Achievement of the shareholder return metric depends on absolute share price performance. For the 2022/23 year grants,
if the share price is between 8p and 38p (based on the non-volume weighted mean average price over the 3 months preceding the vesting date), options will vest on a straight-line basis between nil and 100% of the 30% shareholder return metric. The 2021/22 year grants are similarly assessed, save that the share price range is between 12p and 38p.
Details of the awards can be seen on page 27.

clocktower
30/8/2023
22:38
Hatfull - where did you get 38p strike price from. The shares were initially issued at 35p 10 years ago so that's just make believe. And now you know why I post on here to counter some of the more outlandish statements. Aim is truly the wild west of investing.
kingalf
30/8/2023
21:26
The dilutive comment was taken from the 2023 annual report.I guess 10% of the share capital in options could be considered dilutive. Strikes are up to 38p
hatfullofsky
30/8/2023
21:10
hat, although the last options were nil paid as far as I can recall, I am not so sure when you state they could potential be dilutive, as I thought there was a strike price that was above the current share price and some as high as 10p unless my memory is confused but it was all set out in the last full year accounts which are available online if anyone wants to check.

Please correct me if I am wrong as I would not like to mislead or try to run the share price lower just to jump back in if I felt the news justified it.

Usually there is a bit of insider buying just before major price changing news but that is yet to show its head.

clocktower
30/8/2023
19:15
Why would the directors need to buy when they have so many options ?

10 Employees (6 directors)

At 31/03/23 there were 20.7m (10% of the share capital) options outstanding (2022 10.6m), which are potentially dilutive (13m Directors Share Options)

Huw Jones 9m
Barry Clare 1.2m
Richard Moulson 2.35m
Others 0.2m

hatfullofsky
30/8/2023
18:27
Due in the next 4 months

$500k Phase IIb milestone payment
Breast Cancer study findings
Colorectal Cancer study findings
Radio Sensitisation study findings

hatfullofsky
30/8/2023
17:36
Just wish kight would show more of his hand
markth126
30/8/2023
17:18
Balls of Steel
hatfullofsky
30/8/2023
17:05
I'm now way over 3.5m and my comfort zone but holding for a payout soon in personal opinion. Will never sell them all until buyout deal but posed to top slice at 7/8p. Good luck all. No stop loss for me and got to be in it to win it.
markth126
30/8/2023
16:55
They are in discussions with partner for breast cancer so can't as it's sensitive information. Probably a deal before the end of the year.
wololol
30/8/2023
16:35
just tell me here - I don't have time to watch past presentations.
farrugia
30/8/2023
14:14
Watch the investor meet presentations and you will find out. Old news bro
wololol
30/8/2023
13:35
my question is why is there almost no director buys?
farrugia
29/8/2023
18:10
Well let's hope these significant contracts come to fruition. So much expense and so little to show for it.
Stil, we have the die hard supporters who should really be a little annoyed with the bods but blindly keep the faith. I'm starting to think that some of the most ardent supporters on here are infact the bods themselves.

kingalf
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older

Your Recent History

Delayed Upgrade Clock